Dermapharm Holding SE

 
DE EN
Key facts of the Company
Investor Relations

Factsheet Download

QuickCheck

Ingredients
Pharmaceutical
Ingredients

380+
Marketing authorizations
Marketing
authorisations

>1300
Revenue
Revenue EUR
2020

793.8 million
EBITDA
EBITDA EUR
2020
(unadjusted)
184.5 million

Share

Stock information
ISIN / WKN
DE000A2GS5D8 / A2GS5D
Stock exchange symbol / Reuters symbol
DMP
Type of Shares
bearer shares with no par value (Stückaktien)
First day of trading
9 February 2018
Number of Shares
53.84 million
Stock Exchanges
Regulated Market (Prime Standard) of the Frankfurt Stock Exchange
Index
since 23th September 2019
Analysts
Charlotte Friedrichs, Joh. Berenberg, Gossler & Co. KG
Daniel Wendorff, ODDO BHF Corporates & Markets AG
Alexander Thiel, Jefferies International Ltd.
Dennis Berzhanin, Pareto Securities AS
Dr. Marcus Wieprecht, Stifel European Bank AG
Thomas Wissler, AlsterResearch
Designated Sponsors
Joh. Berenberg, Gossler & Co. KG
Stifel European Bank AG
Paying agent
Quirin Privatbank AG
Shareholder Structure

Shareholder Structure

Shareholder Structure

Company

Company Profile

Dermapharm - Pharmaceutical Excellence “Made in Europe”:

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

In the "Branded pharmaceuticals and other healthcare products" segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

In the "Herbal extracts" segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm's business model also includes the "Parallel import business" segment that operates under the "axicorp" brand. Based on revenue, Dermapharm was among the top five parallel import companies in Germany in 2020.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, Dermapharm has continuously optimised its business over the past 30 years and sought external growth opportunities in addition to organic growth. Dermapharm is firmly committed to continuing on this profitable growth course in the future.

Boards

Management Board

Dr. Hans-Georg Feldmeier CEO, Pharmacist

Dr. Hans-Georg Feldmeier is the Chairman of the Management Board at Dermapharm. He joined the company in 2003 as project manager and was responsible for the construction of the new production facilities in Brehna. Since 2009, he has been Chief Production & Development Officer of Dermapharm. Dr. Feldmeier began his professional career in 1987 at Berlin Chemie. He played a decisive role in the modernization of the company after the fall of the Berlin Wall. In 2002, he was head of the supply center at Schering Aktiengesellschaft, Berlin.

Karin Samusch CBDO

Karin Samusch is Dermapharm’s Chief Business Development Officer. She joined the company in 1991 and has been responsible for business development, international affairs, regulatory affairs and pharmacovigilance ever since. Prior to joining Dermapharm she worked for the pharmaceutical company Dorsch GmbH and the seal producer Feodor Burgmann GmbH & Co. KG.

Dr. Jürgen Ott CMO

Since October 1, 2019 is Dr. Jürgen Ott is the Chief Marketing Officer, responsible for Marketing and Sales at Dermapharm. He holds a doctorate in chemistry and has extensive experience in the consumer goods and pharmaceutical industries. His last position since 2010 was Head of Marketing Germany, since 2014 Head of Marketing & Sales Germany and from 2017 Regional Head Central Europe at Bionorica SE, a manufacturer of herbal pharmaceuticals. Prior that he spent more than 11 years as Key Account Manager and Brand Manager at Procter & Gamble.

Hilde Neumeyer
Hilde Neumeyer CFO, CCO

Hilde Neumeyer has been Chief Financial Officer of the Dermapharm Group since July 1, 2020. She has been Chief Compliance Officer since the IPO and has developed a Governance, Risk & Compliance System as well as successfully established it within the Group. She has been working for Dermapharm in Finance and Accounting since October 1, 2000 and took over as Head of Group Accounting in 2005. Through the development of the accounting department, she has permanently and systematically adapted to new challenges and successfully integrated various acquisitions into the Group's reporting structures. Before joining the Dermapharm Group, Ms. Neumeyer worked for Novartis in accounting for 10 years.

Supervisory Board

Wilhelm Beier

Wilhelm Beier was born in Eicherscheid (Bad Münstereifel), Germany, on April 21, 1956. Starting his career in 1981, he held various positions in the pharmaceuticals industry, including a managing director of the German subsidiaries of an international pharmaceuticals manufacturer. After founding Dermapharm in 1991, Mr. Beier served as Chief Executive Officer of Dermapharm AG.

In 2017, he was appointed chairman of the supervisory board of Dermapharm.

Mr. Beier and his family hold the majority of the company's shares via Themis Beteiligungs AG.

Dr. Erwin Kern

Dr Erwin Kern was born on July 6, 1960 in Karlsruhe, Germany. In 1986, Dr. Kern completed his studies in business administration at the Ludwig Maximilian University in Munich. In 1989, he received his doctorate in economics from the University of Paderborn. Dr. Kern began his professional career in 1986 as Managing Director of HBK-Handel und Beteiligungen Kern GmbH & Co. KG. From 1991 onwards, he was a member of the management of Kies und Beton Baden-Baden GmbH & Co. Holding KG and Kies und Beton AG Baden-Baden. In 2007, Dr. Kern took over the chairmanship of the management of these companies, which he still holds today. Since 2003, he has been President of the Federal Association of the German Ready-Mixed Concrete Industry (BTB). (BTB) since 2003 and was Chairman from 2008 to 2011 and Vice Chairman from 2011 to 2013 of Construction Products Europe (CPE) (Association of European Construction Materials Manufacturers).

Dr Kern was appointed as a member of the Supervisory Board of Dermapharm Holding SE in 2017. In addition to his position at Dermapharm, Dr Kern was and is active in various companies and associations in the stone and earth industry that are not listed on the stock exchange.

Lothar Lanz

Lothar Lanz was born on October 1, 1948 in Bihlafingen, Germany. From 1969 to 1974, Mr. Lanz studied business administration at the universities of Stuttgart and Berlin and graduated with a degree in business administration. Mr. Lanz began his professional career as an audit assistant for an auditor and tax consultant in Berlin. In 1977, Mr. Lanz joined Bayerische Hypotheken- und Wechselbank AG, where he served as branch manager from 1983 to 1990. In 1991, Mr. Lanz became a member of the Board of Management of H.S.B. HYPO Service-Bank AG, Munich. In 1996, he moved to Nassauische Sparkasse, Wiesbaden, where he also became a member of the Board of Management. In the same year, Mr. Lanz moved to the then ProSieben Media AG (now ProSiebenSat.1 Media AG) as Chief Financial Officer, a post he held until 2008. From 2009 to 2014, Mr. Lanz was a member of the Executive Board of Axel Springer AG (now Axel Springer SE), where he served as Chief Financial and Operating Officer.

Mr. Lanz was appointed as a member of the Supervisory Board of Dermapharm Holding SE in 2017. In addition, he is currently Chairman of the Supervisory Board of Home 24 SE and a member of the Supervisory Board of TAG Immobilien AG and the unlisted Bauwert AG. Until 2019, he was also a member of the Supervisory Board of Axel Springer SE and Chairman of the Supervisory Board of Zalando SE.

Financial Figures
 Financial Figures    2020   2019   2018   2017   2016   2015   2014  
 Revenue  in EUR million   793.8   700.9   572.4   467.1   444.5   384.8   391.3  
 Adjusted EBITDA  in EUR million   200.7   177.6   143.4   112.9   102.7   -   -  
 Adjusted EBITDA Margin  in %   25.3   25.3   25.1   24.2   23.1   -   -  
 Unadjusted EBITDA  in EUR million   184.5   168.5   139.6   110.2   102.7   84.7   72.4  
 Unadjusted EBITDA Margin  in %   23.2   24.0   24.4   23.6   23.1   22.0   18.5  
 Operating income  in EUR million   136.9   119.5   107.5   92.1   86.8   43.3   60.8  
 Earnings before taxes  in EUR million   125.3   110.1   104.2   88.0   82.9   55.3   35.5  
 Profit or (loss) for the period  in EUR million   85.9   77.8   75.2   77.7   77.0   52.4   33.2  
 Earnings per share  in EUR   1.59   1.43   1.41   1.56   1.54   -   -  
 Dividend  in EUR   0.88   0.80   0.77   -   -   -   -  
 Balance sheet  in EUR million   1,224.4   1,044.9   704.6   415.3   311.7   296.7   330.6  
 Equity  in EUR million   324.6   284.5   256.1   73.7   60.8   44.4   34.0  
 Equity ratio  in %   26.5   27.2   36.3   17.7   19.5   15.0   10.3  
 Cash and cash equivalents  in EUR million   120.3   115.0   212.5   6.3   3.8   2.8   11.6  
 Net debt  in EUR million   486.8   465.4   95.2   258.5   173.7   189.7   210.8  

 

Picture Archive
Locations

IR Contact & Events

IR Contact

IR Contact

If you have any further questions, please do not hesitate to contact us. You can contact us via e-mail or directly by telephone. In addition, we offer you the opportunity to join our IR news service in order to receive information from Dermapharm Holding SE promptly. Furthermore, all current dates can be found in the financial calendar.

Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany

Contact person:
Britta Hamberger
Investor Relations & Corporate Communications
Phone: +49 (0) 89 641 86 233
Fax: +49 (0) 89 641 86 165

IR News Service

IR News Service

We are happy to include you in our news service! Please simply fill in the form below and you will receive information on the subject Investor Relations.
Financial Calendar

30 March 2021: Publication of preliminary figures for the 2020 annual financial statements

13 April 2021: Publication of annual financial statements 2020

18 May 2021: Publication of quarterly statement (reporting date Q1 2021)

23 June 2021: Annual General Meeting

24 August 2021: Publication of preliminary figures for the 2021 half-year

07 September 2021: Publication of the 2021 half-year report

16 November 2021: Publication of quarterly statement (reporting date Q3 2021)

Corporate Governance

Voting Rights Notification

2020-10-15 | Voting Rights Announcement of Wilhelm Beier

2018-02-13 | Voting Rights Announcement of Wilhelm Beier

2018-02-09 | Voting Rights Announcement of Wilhelm Beier

Directors‘ Dealings

2020-07-22 | Announcement of Hilde Neumeyer

2020-02-02 | Announcement of Hilde Neumeyer

2020-11-18 | Announcement of Hilde Neumeyer

2020-10-15 | Announcement of Themis Beteiligungs-Aktiengesellschaft

2020-10-14 | Announcement of Hilde Neumeyer

2019-08-08 | Announcement of Karin Samusch

2019-07-01 | Announcement of Themis Beteiligungs-Aktiengesellschaft

2018-03-13 | Announcement of Themis Beteiligungs-Aktiengesellschaft

2018-02-09 | Announcement of Themis Beteiligungs-Aktiengesellschaft

2018-02-09 | Announcement of Themis Beteiligungs-Aktiengesellschaft

Statement of Compliance

Updated Declaration of Conformity 2021 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Updated Declaration of Conformity 2020 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Updated Declaration of Conformity 2019 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Updated Declaration of Conformity 2018 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Declaration of Conformity 2018 with the German Corporate Governance Code pursuant to Section 161 of the German Stock Corporation Act (AktG)

Compliance

Compliance Manual (Code of Conduct)

Other Documents

Articles of Association of Dermapharm Holding SE 2021 (German)

Management Board remuneration system (German)

Articles of Association of Dermapharm Holding SE 2020 (German)

Rules of Procedure of Dermapharm Holding SE

UK Modern Slavery Act Statement 2020

UK Modern Slavery Act Statement 2019

Annual General Meeting

Documents

The Annual General Meeting of Dermapharm Holding SE, based in Grünwald, Munich district, will take place on June 23, 2021 at 10:00 a.m. as a virtual general meeting in the company's premises, Lil-Dagover-Ring 7, 82031 Grünwald.

Dermapharm Holding SE ‒ Annual Report 2019 including the consolidated financial statements, the combined management report, the explanatory report of the Management Board on the disclosures pursuant to Sections 289a (1), 315a (1) German Commercial Code (HGB) and the report of the Supervisory Board for financial year 2020

Dermapharm Holding SE - Individual financial statement 2020 according to German Commercial Code (HGB) including the adopted annual financial statements of Dermapharm Holding SE (German)

Invitation including the agenda and the disclosures according to § 124a sentence 1 no. 2 and 4 AktG (German)

Report of the Supervisory Board for the financial year 2020 (German)

Articles of Association of Dermapharm Holding SE (German)

Explanation of the Shareholders' Rights 2021 (German)

Additions to the agenda: There are currently no requests by shareholders to put additional items on the agenda that need to be published.

Countermotions and election nominations: There are currently no countermotions and/or election nominations by shareholders that need to be published.

Voting Results

Voting results of the Annual General Meeting 2021

Voting results of the Annual General Meeting 2020

Presentation

Dermapharm Holding SE – AGM 2021 Presentation

Dermapharm Holding SE – AGM 2020 Presentation

Archive

Annual General Meeting 2020

Dermapharm Holding SE ‒ Annual Report 2019 including the consolidated financial statements, the combined management report, the explanatory report of the Management Board on the disclosures pursuant to Sections 289a (1), 315a (1) German Commercial Code (HGB) and the report of the Supervisory Board for financial year 2019

Dermapharm Holding SE - Individual financial statement 2019 according to German Commercial Code (HGB) including the adopted annual financial statements of Dermapharm Holding SE (German)

Invitation including the agenda and the disclosures according to § 124a sentence 1 no. 2 and 4 AktG (German)

Report of the Supervisory Board for the financial year 2019 (German)

Articles of Association of Dermapharm Holding SE (German)

Explanation of the Shareholders' Rights 2020 (German)

Annual General Meeting 2019

Dermapharm Holding SE ‒ Annual Report 2018 including the consolidated financial statements, the combined management report, the explanatory report of the Management Board on the disclosures pursuant to Sections 289a (1), 315a (1) German Commercial Code (HGB) and the report of the Supervisory Board for financial year 2018

Dermapharm Holding SE - Individual financial statement 2018 according to German Commercial Code (HGB) including the adopted annual financial statements of Dermapharm Holding SE (German)

Invitation including the agenda and the disclosures according to § 124a sentence 1 no. 2 and 4 AktG (German)

Report of the Supervisory Board for the financial year 2018

Articles of Association of Dermapharm Holding SE (German)

Explanation of the Shareholders' Rights 2019 (German)

Voting results of the Annual General Meeting 2019

Dermapharm Holding SE – AGM 2019 Presentation

Annual General Meeting 2018

Dermapharm Holding SE - Annual report 2017 including the consolidated financial statements, the management report on the Group’s situation and the report of the Supervisory Board each for the financial year 2017

Dermapharm Holding SE – Individual financial statement according to German Commercial Code (HGB) (German)

Invitation including the agenda and the disclosures according to § 124a sentence 1 no. 2 and 4 AktG

Report of the Supervisory Board (as of May 18, 2018)

Articles of Association of Dermapharm Holding SE (German)

Explanation of the Shareholders' Rights 2018 (German)

Dermapharm AGM 2018 – Voting Results

Dermapharm Holding SE – AGM 2018 Presentation

Publications

Corporate News

2021-09-07 | Dermapharm publishes H1 2021 report, confirms outlook for 2021 overall

2021-08-24 | Dermapharm Holding SE: Adjusted EBITDA up almost 50% in H1 2021

2021-07-07 | Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH

2021-06-23 | Dermapharm Holding SE: Annual General Meeting approves dividend distribution of EUR 0.88 per share

2021-05-18 | Dermapharm Holding SE: accelerated EBITDA growth in Q1 2021

2021-04-30 | Dermapharm Holding SE: Federal Minister of Health Jens Spahn joins opening ceremony for vaccine manufacturing facility at subsidiary Allergopharma GmbH & Co. KG

2021-04-13 | Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures

2021-03-30 | Dermapharm posts growth despite COVID-19 pandemic – consolidated revenue and EBITDA continue to rise

2021-02-12 | Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021

2020-11-16 | Dermapharm Holding SE continues on its growth course in third quarter of 2020

2020-09-30 | Dermapharm Holding SE – subsidiary axicorp GmbH breaks ground for a new building near Frankfurt/Main

2020-09-10 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine

2020-09-09 | Dermapharm publishes Half-Year Financial Report 2020 and confirms growth course despite corona pandemic

2020-08-21 | Dermapharm remains on growth course despite corona pandemic in the first half of 2020

2020-06-17 | Dermapharm Holding SE: Annual General Meeting approves dividend payout of EUR 0.80 per share

2020-05-19 | Growth in the first quarter of 2020 despite the corona pandemic

2020-04-08 | Dermapharm confirms profitable growth in 2019 and presents positive outlook for 2020 despite corona

2020-03-31 | Dermapharm successfully acquires Allergopharma

2020-03-25 | Dermapharm continues its profitable growth in 2019

2020-02-19 | Dermapharm Holding SE to acquire Allergopharma

2020-02-05 | Dermapharm Holding SE opens new logistics center in Brehna

2019-11-20 | Dermapharm Holding SE continues to drive the company’s growth in the third quarter of 2019

2019-09-12 | Dermapharm confirms profitable growth in first half of 2019

2019-08-23 | Dermapharm continues on its profitable growth course in first half of 2019

2019-07-29 | Dermapharm Holding SE: Dr. Jürgen Ott named new CMO

2019-07-01 | Dermapharm Holding SE with increased free float

2019-06-06 | Dermapharm Holding SE acquires a stake in fitvia

2019-06-04 | Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.77 per share

2019-05-21 | Dermapharm Holding SE: First quarter of 2019 characterized by profitable growth

2019-04-26 | Dermapharm to expand capacities at its main production site in Brehna

2019-04-17 | Fiscal year 2018

2019-04-03 | Preliminary figures for fiscal year 2018

2019-03-04 | Dermapharm Holding SE acquires stake in cannabis producer for pharmaceutical applications

2019-02-21 | Dermapharm continues to drive development of new products

2019-01-23 | Dermapharm continues expansion course

2018-11-20 | Third Quarter 2018

2018-11-18 | Signing of contract for the acquisition of EUROMED S.A.

2018-11-16 | Dermapharm takes legal action against approval of a competitor product

2018-09-12 | First Half-Year 2018

2018-08-21 | Preliminary figures for the first half of 2018

2018-06-26 | AGM 2018

2018-05-18 | First Quarter 2018

2018-04-27 | Fiscal year 2017

2018-04-09 | Preliminary Figures 2017

2018-02-08 | Pricing

2018-01-26 | IPO Details

2018-01-15 | INTENTION TO FLOAT

Ad Hoc News

2021-07-07 | Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH

2021-02-12 | Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccineproduction to make a high double-digit million € contribution to sales in 2021

2020-09-10 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE

2020-02-19 | Dermapharm Holding SE: Acquisition of Allergopharma

2019-06-06 | Dermapharm Holding SE acquires a stake in fitvia

2019-03-04 | Dermapharm Holding SE acquires stake in cannabis producer for pharmaceutical applications

2018-11-18 | Signing of contract for the acquisition of EUROMED S.A.

2018-02-08 | Pricing

Financial Reports

Dermapharm Holding SE - Half-year Financial Report 2021

Dermapharm Holding SE - Interim Statement first quarter 2021

Dermapharm Holding SE - Individual Financial Statement 2020 according to German Commercial Code (HGB) (German)

Dermapharm Holding SE - Annual report 2020

Dermapharm Holding SE - Interim Statement third quarter 2020

Dermapharm Holding SE - Half-year Financial Report 2020

Dermapharm Holding SE - Interim Statement first quarter 2020

Dermapharm Holding SE - Individual Financial Statement 2019 according to German Commercial Code (HGB) (German)

Dermapharm Holding SE - Annual report 2019

Dermapharm Holding SE - Interim Statement third quarter 2019

Dermapharm Holding SE - Half-year Financial Report 2019

Dermapharm Holding SE - Interim Statement first quarter 2019

Dermapharm Holding SE - Individual financial statement 2018 according to German Commercial Code (HGB) (German)

Dermapharm Holding SE - Annual report 2018

Dermapharm Holding SE - Interim Statement third quarter 2018

Dermapharm Holding SE - Half-year Financial Report 2018

Dermapharm Holding SE - Interim Statement first quarter 2018

Dermapharm Holding SE - Individual financial statement according to German Commercial Code (HGB) (German)

Dermapharm Holding SE - Annual report 2017

Dermapharm Holding SE - IFRS Financial Statements as of September 30,2017

Dermapharm AG - IFRS Consolidated Financial Statements and Group Management Report as of December 31, 2016

Presentations

Dermapharm Holding SE - H1/2021 Presentation

Dermapharm Holding SE - Q1/2021 Presentation

Dermapharm Holding SE - FY 2020 Presentation

Dermapharm Holding SE - Q3/2020 Presentation

Dermapharm Holding SE - H1/2020 Presentation

Dermapharm Holding SE - Q1/2020 Presentation

Dermapharm Holding SE - FY 2019 Presentation

Dermapharm Holding SE - Q3/2019 Presentation

Dermapharm Holding SE - H1/2019 Presentation

Dermapharm Holding SE - Q1/2019 Presentation

Dermapharm Holding SE - FY 2018 Presentation

Dermapharm Holding SE - Q3/2018 Presentation

Dermapharm Holding SE - H1/2018 Presentation

Dermapharm Holding SE - Q1/2018 Presentation

Other Documents

Prospectus

Sustainability

CSR-Reports

Dermapharm Holding SE - CSR-Report 2020

Dermapharm Holding SE - CSR-Report 2019

Dermapharm Holding SE - CSR-Report 2018

GRI-Index

The following GRI Index is oriented towards the current standards of the Global Reporting Initiative 2016 and partly corresponds to the requirements of the „core“ option. To be precise, the following information correspond to the requirements of „GRI 102: General Disclosures 2016“ with the exception of the codes 102-38, 102-39, 102-42, 102-43, 102-44 and 102-46, for each of which an explanation is given for why they have been left out.

 GRI-Code  GRI-Description   Reference   Comment  
102-1 Name of the organization Dermapharm Holding SE
102-2 Activities, brands, products, and services 2020 Annual Report, page 15 2020 CSR Report, pages 7-8
102-3 Location of headquarters Lil-Dagover-Ring 7 82031 Grünwald Germany
102-4 Location of operations IR Website, section "company"
102-5 Ownership and legal form Dermapharm has been listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange since February 9, 2018. At 65.05%, the majority of no-par value shares are owned by Themis Beteiligungs-Aktiengesellschaft. 34.95% of the shares of Dermapharm Holding SE are in free float as defined by Deutsche Börse. Detailed information is available at www.ir.dermapharm.de and in the Annual Report 2020, pages 22-23.
102-6 Markets served
102-7 Scale of the organization In 2020, the Dermapharm Group employed an annual average of 2,311 people. The Group comprises 56 companies, 28 of which are based in Germany (see Annual Report 2020, Organizational Chart p. 30). The Dermapharm Group currently has more than 1,300 drug approvals.
102-8 Information on employees and other workers Based on a current data query of all Group companies, the following statistics emerged as of the reporting date of December 31, 2020: Of 2,462 employees, 1,469 were women and 985 were men. 2,196 of the positions were permanent and 228 temporary. 2,108 of the jobs were full-time and 346 were part-time. 80% of the jobs were in Germany, 8% in Spain, 3% in Austria, 3% in Poland, 1% each in China, Italy, Croatia, Switzerland and Ukraine, and <1% in the UK).
102-9 Supply chain 2020 Annual Report, Risk Report, p. 50-63
102-10 Significant changes to the organization and its supply chain No significant changes.
102-11 Precautionary Principle or approach No formalized precautionary approach exists yet
102-12 External initiatives CSR Report 2020, page 31, Section: "Responsible marketing"
102-13 Membership of associations CSR Report 2020, page 31, Section: "Responsible marketing"
102-14 Statement from senior decision-maker CSR-Bericht 2020, page 5, Section: "Foreword by the management board"
102-15 Key impacts, risks, and opportunities 2020 Annual Report p. 50-63: Opportunity and risk report 2020 CSR Report, page 4: Foreword 2020 CSR Report: page 10: Sustainability Strategy
102-16 Values, principles, standards, and norms of behavior CSR Report 2020, page 4: Foreword Annual Report 2020, pages 50-62: Opportunity and risk report Annual Report 2020, pages 69-73: Corporate Governance Report
102-17 Mechanisms for advice and concerns about ethics CSR Report 2020, pages 31-33: Governance and compliance Annual Report 2020, pages 50-62: Opportunity and risk report Annual Report 2020, pages 69-71: Corporate governance report
102-18 Governance structure 2020 Annual Report, page 6, Section "Member of the management board" 2020 Annual Report, pages 69-74: Corporate Governance Statement
102-19 Delegating authority 2020 Annual Report, S. 69-77: Corporate Governance Report: Information on Corporate Governance Practices
102-20 Executive-level responsibility for economic, environmental, and social topics Dr. Hans-Georg Feldmeier, CEO
102-21 Consulting stakeholders on economic, environmental, and social topics CSR Report 2020, pages 29-30: Governance and compliance
102-22 Composition of the highest governance body and its committees Annual Report 2020, pages 69-74: Corporate Governance Report
102-23 Chair of the highest governance body Annual Report 2020, pages 69-74: Corporate Governance Report
102-24 Nominating and selecting the highest governance body Annual Report 2020, pages 50-62: Opportunity and risk report Annual Report 2020, pages 69-74: Corporate Governance Report
102-25 Conflicts of interest Annual Report 2020, pages 50-62: Opportunity and risk report Annual Report 2020, pages 69-74: Corporate Governance Report
102-26 Role of highest governance body in setting purpose, values, and strategy Annual Report 2020, pages 9-11: Report of the Supervisory Board Annual Report 2020, pages 69-74: Corporate Governance Report Annual Report 2020, page 146: Information on the Executive Board and Supervisory Board Annual Report 2020, pages 50-62: Opportunity and risk report
102-27 Collective knowledge of highest governance body Annual Report 2020, pages 69-74: Corporate Governance Report Annual Report 2020, page 146: Information on the Executive Board and Supervisory Board
102-28 Evaluating the highest governance body’s performance Annual Report 2020, page 31: Fundamentals of the Group
102-29 Identifying and managing economic, environmental, and social impacts Annual Report 2020, pages 50-63: Opportunity and risk report
102-30 Effectiveness of risk management processes Annual Report 2020, pages 50-63: Opportunity and risk report Annual Report 2020, pages 9-11: Report of the Supervisory Board
102-31 Review of economic, environmental, and social topics 2020 Annual Report, pages 50-63: Opportunity and risk report 2020 Annual Report, pages 9-11: Report of the Supervisory Board CSR Report 2020, page 10: Sustainability strategy and targets
102-32 Highest governance body’s role in sustainability reporting The Board of Management and Supervisory Board are responsible for the final review of the reported sustainability information.
102-33 Communicating critical concerns Annual Report 2020, pages 50-62: Opportunity and risk report Annual Report 2020, pages 69-74: Corporate Governance Report
102-34 Nature and total number of critical concerns Annual Report 2020, pages 50-62: Opportunity and risk report Annual Report 2020, pages 69-74: Corporate Governance Report
102-35 Remuneration policies Annual Report 2020, pages 69-77: Corporate Governance Report
102-36 Process for determining remuneration Annual Report 2020, pages 69-77: Corporate Governance Report
102-37 Stakeholders’ involvement in remuneration 2020 Annual Report, pages 69-77: Corporate Governance Report Voting results of the last Annual General Meeting: https://ir.dermapharm.de/pdf/Dermapharm_Holding_SE-Abstimmungsergebnisse_Uebersicht_voHV20.pdf
102-38 Annual total compensation ratio We do not consider the disclosures required under GRI Code 102-38 to be material for the assessment of our compensation structures
102-39 Percentage increase in annual total compensation ratio We do not consider the disclosures required under GRI Code 102-38 to be material for the assessment of our compensation structures
102-40 List of stakeholder groups 2020 CSR Report, pages 29-30: Governance and compliance
102-41 Collective bargaining agreements 26% of our employees in Germany are subject to collective bargaining agreements.
102-42 Identifying and selecting stakeholders No formalized identification and selection of stakeholders with regard to ESG issues exists yet
102-43 Approach to stakeholder engagement There is still no formalized stakeholder engagement with regard to ESG issues
102-44 Key topics and concerns raised We take ESG issues and suggestions raised by our stakeholders very seriously. However, there is not yet a systematic identification of important ESG issues of our stakeholders.
102-45 Entities included in the consolidated financial statements Annual Report 2020, p. 92-94: Principles and scope of consolidation
102-46 Defining report content and topic Boundaries There is not yet a systematic procedure for determining and thematically delimiting the content of the report.
102-47 List of material topics CSR Report 2020, page 10: Sustainability strategy and targets
102-48 Restatements of information No significant changes.
102-49 Changes in reporting With the CSR Report 2020, reporting was supplemented with further ESG key figures as well as an initial indicative SDG and GRI index.
102-50 Reporting period 01.01.2020 to 31.12.2020
102-51 Date of most recent report April 13, 2021
102-52 Reporting cycle Annually
102-53 Contact point for questions regarding the report CSR Report 2020, page 35
102-54 Claims of reporting in accordance with the GRI Standards The sustainability reporting for the 2020 financial year was prepared in accordance with the GRI standards and meets the requirements of the GRI "Core" option in most respects.
102-55 GRI content index Available on this page
102-56 External assurance Dermapharm's CSR report has not been audited.
201-1 Direct economic value generated and distributed Annual Report 2020, page 131: Key figures employees
Annual Report 2020, page 2: Key figures economy
Annual Report 2020, pages 80f: Profit and loss account
Annual Report 2020, page 84: Cash flow statement
Annual Report 2020, page 39: Information by business sector
Annual Report 2020, page 131: personell expenses
201-2 Financial implications and other risks and opportunities due to climate change CSR Report 2020, page 2: Environmental key figures
CSR Report 2020, pages 16-17: Water management
Annual Report 2020, pages 50-63: Opportunity and risk report
201-3 Defined benefit plan obligations and other retirement plans Annual Report 2020, page 131: Key figures employees
Annual Report 2020, page 103: Retirement provision
201-4 Financial assistance received from government Annual Report 2020, page 103: Research and development costs
Annual Report 2020, page 100: Property, plant and equipment
Annual Report 2020, pages 90f: Valuation/accounting principles for Property, plant and equipment
205-1 Operations assessed for risks related to corruption Compliance: see Compliance Manual online
Annual report 2020, pages 69-70: Declaration of Compliance=Values and Compliance
Annual report 2020, pages 75-77: Compensation Report=Values and Compliance
Annual report 2020, pages 72-73: Members of the AR=Values and Compliance
Annal report 2020, page 146: Members of the AR=Values and Compliance
Annual Report 2020, pages 50-63: Compliance in the Opportunity and risk report
Annual Report 2020, pages 69-77: Compliance in the Corporate Governance Report
Annual Report 2020, pages 50-63: Opportunity and risk report
205-2 Communication and training about anti-corruption policies and procedures Annual Report 2020, pages 50-63: Compliance in the Opportunity and risk report
Annual Report 2020, pages 69-77: Compliance in the Corporate Governance Report
205-3 Confirmed incidents of corruption and actions taken CSR Report 2020, page 29: Ethical behavior
Annual Report 2020, pages 50-63: Opportunity and risk report
Annual Report 2020, pages 50-63: Compliance in Opportunity and risk report
Annual Report 2020, pages 69-77: Compliance in the Corporate Governance Report
206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices CSR Report 2020, page 29: Ethical behavior
301-1 Materials used by weight or volume CSR Report 2020, pages 17-18: Recycled waste materials
301-2 Recycled input materials used CSR Report 2020, page 10: Efficient resource and energy management
302-1 Energy consumption within the organization CSR Report 2020, pages 15f.: Environmental concerns
302-2 Energy consumption outside of the organization CSR Report 2020, pages 15f.: Environmental concerns
302-4 Reduction of energy consumption CSR Report 2020, pages 14-15.: Energy consumption of the Dermapharm Group of Companies
303-1 Interactions with water as a shared resource CSR Report 2020, pages 16-17 Recycled waste materials
306-1 Waste generation and significant waste-related impacts CSR Report 2020, pages 17-18: Waste management
CSR Report 2020, pages 17-18: Recycled waste materials
306-2 Management of significant waste-related impacts CSR Report 2020, pages 10+18: Efficient resource and energy management CSR Report 2020, pages 17-18: Waste management
CSR Report 2020, pages 17-18: Recycled waste materials
403-1 Occupational health and safety management system CSR Report 2020, page 27: Occupational health management
403-3 Occupational health services CSR Report 2020, page 27: Occupational health management
403-4 Worker participation, consultation, and communication on occupational health and safety CSR Report 2020, pages 26-27: Safety and operational suggestion scheme
403-5 Worker training on occupational health and safety CSR Report 2020, pages 23-25: Education and training
403-6 Promotion of worker health CSR Report 2020, page 27: Occupational health management
403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships CSR Report 2020, page 27: Occupational health management
403-9 Work-related injuries CSR Report 2020, pages 26-27: Safety and operational suggestion scheme
Annual Report 2020, page 131: Key figures employees
404-2 Programs for upgrading employee skills and transition assistance programs CSR Report 2020, pages 23-25: Education and training
405-1 Diversity of governance bodies and employees CSR Report 2020, page 26: Diversity and employee participation
2020 annual report, pages 72-73: Objectives of the Supervisory Board for its composition
Annual Report 2020, page 131: Key figures employees
Annual Report 2020, page 6: Board of Directors/Executive Management (CEO/CFO/CMO/CBDO)
Annual report 2020, page 146 Board of Directors/Management/Members of the Supervisory Board
408-1 Operations and suppliers at significant risk for incidents of child labor CSR-Report 2020, page 31: Ethical and lawful conduct
409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor CSR Report 2020, page 31: Ethical and lawful conduct
416-1 Assessment of the health and safety impacts of product and service categories CSR Report 2020, page 8: Branded medicines and other health products
CSR Report 2020, page 10: Sustainability strategy and goals
ESG-Data
Environment
 Environment  2018   2019   2020  
 Sales in EUR million  572.4   700.9   793.8  
 Number of employees1  1,635   1,857   2,311  
 Power consumption* in kWh  10,899,870   10,855,164   17,223,629  
 Gas consumption* in kWh  12,515,058   12,307,952   19,348,542  
 Water consumption* in m3  61,838   63,479   85,913  
 Wastewater consumption* in m3  61,218   63,480   85,913  
 Waste volume* in t  2,218   4,223   1,589  

*German-speaking production locations only
1 Number of employees based on average headcount.

A more detailed contextualization of the environmental data can be found in the current CSR Report 2020, pp. 12-18.

Social
 Social  2018   2019   2020  
 Sales in EUR million  572.4   700.9   793.8  
 Number of employees1  1,635   1,857   2,311  
 Fluctuation rate2 7.6%   6.7%   6.3%  
 Total proportion of women    56.7%   59.9%  
 Proportion of women in management (management level 1 and 2)  46.7%   47.9%   48.9%  
     thereof management level 1       39.3  
     thereof management level 2       53.8  
 Proportion of fixed-term contracts 13.6%   10.5%   9.3%  
 Part-time employees 15.9%   13.1%   14.1%  
 Average sick days per employee 16.0   16.9   16.5  
 Thousand-man quota (TMQ) 12.0   17.0   16.0  
 Number of trainees 39   46   51  
 Number of theses in cooperation with Dermapharm 15   31   53  
 Number of suggestions for improvement via the company suggestion scheme 41   57   93  
 Proportion of employees with severe disabilities 2.1%   2.3%   2.9%  
 Average age 42.9   41.4   42.6  

1 Number of employees based on average headcount.
2 Calculation according to the Schlüter formula on the basis of the headcount at the beginning of the period plus additions.
The Schlüter formula takes into account the fact that the headcount is a key date figure.
The staff departures represent a period variable.

For a more detailed contextualization of the social data, see the current CSR Report 2020, pp. 23-27.

Governance

Compliance at Dermapharm:

Detailed information on compliance and governance at Dermapharm can be found in our Dermapharm Code of Conduct as well as in the Dermapharm CSR Report 2020.

Maintain high standards:

Dermapharm is committed to the following Good Practices for the pharmaceutical industry:
Good Clinical Practice (GCP)
Good Distribution Practice (GDP)
Good Manufacturing Practice (GMP)
Good Pharmakovigilance Practice (GVP)

Association memberships:

Dermapharm is a member of the BPI: Member list of the Federal Association of the Pharmaceutical Industry
and at the AKG: Member list of the Pharmaceutical and Cooperation in Health Care e.V.

No animal testing:

In 2020, no animal testing took place at Dermapharm.

ESG-Highlights
Energy-Efficient Buildings

Conversion and new buildings for more environmentally friendly production

Conversion and new buildings for more environmentally friendly production We commissioned a new logistics centre in Brehna at the end of 2019. The centre complies with Good Distribution Practice (GDP), a set of standards adopted by the EU in 2013 to ensure a high level of product quality in pharmaceuticals by avoiding falsified medicines and errors in the manufacturing process. The new building also meets the current energy efficiency criteria for buildings laid down in the German Energy Saving Regulation (Energieeinsparverordnung, "EnEV") 2014. Its features also include effective thermal insulation, an air-to-water heat pump and an active specialised ventilation system. In the interests of ecology and improved insulation, the building is also fitted with a green roof. This building – the third at the Brehna site – also boasts another energy feature: Pharmaceuticals must ordinarily be stored at temperatures ranging from 15 °C to 25 °C, which given the ever hotter summers is only achieved by means of costly cooling using air conditioning units.

At mibe we use insulation from the green roof and nightly ventilation to comply with the storage requirements. Large ventilators are used during the night to draw cool outside air into the storage areas and enable compliance with the temperature limit. A particular highlight in reducing CO2 emissions was the installation of a 610,000 kWh solar power unit in the first quarter of 2021. This can satisfy just under 10% of current electricity demand at the Brehna site. It also enables us to isolate the roof cladding against heat radiation even better and reduce power spikes.

Energy-Efficient Buildings 1

In autumn 2020, we launched another new construction project at subsidiary axicorp, with a stateof-the-art production, storage and administration building set to replace the former leased premises. As well as meeting the energy standards currently in force (EnEV) in 2020, three-quarters of the roofing space is designed as an extensive green roof. Energy demand will be reduced by an air-to-water heat pump and a condensing gas boiler. Fresh water consumption will also be reduced by using rainwater from the roof to flush the toilets. Furthermore, our subsidiary Melasan in Austria moved into a new administration and production building last year that fulfils the current energy efficiency standards and additionally features a rainwater infiltration system that goes some way to compensate for soil sealing.

Energy-Efficient Buildings 2

We also meet stringent environmental protection standards at all of our other production sites and conform to new regulatory requirements on an ongoing basis. Our production sites are located in established industrial areas and business parks. Before acquiring companies and thus taking over their locations, we review the ecological risks as part of a due diligence process. In addition, we check our production sites as part of regular energy audits. The production sites of mibe, Anton Hübner and Trommsdorff were last analysed in 2019 in accordance with DIN EN 16247-1. Within the production sites of Allergopharma and Melasan, an energy audit is planned for the end of 2021. In addition, the knowledge gained about potential energy savings will be taken into account in the planning of projects such as the new axicorp building.

Use of Raw Materials

Resource Management at Euromed

Euromed, our Spanish subsidiary and manufacturer of herbal pharmaceuticals, has committed to supporting sustainable agriculture. As such, stringent quality control from raw material to waste disposal is of key importance for Euromed. Its main production facility in Barcelona, which processes more than 5,000 tonnes of biomass into herbal extracts each year, has obtained multiple production certifications including ISO 14001 for ecological sustainability. Among other things, the organic waste generated during production is passed on to companies that generate environmentally friendly energy, is composted, or is used as feed for livestock.

Euromed also focuses on exploiting the full potential of the plants used, for instance its product "Lipidic Sterolic Saw Palmetto Extract" (SPE) which as the name suggests is sourced from saw palmetto. The ripe berries of this wild plant, which is considered endangered, are harvested exclusively in Florida and a small part of Georgia, USA. Euromed operates its own facility close to Lake Okeechobee in Florida so that it can rapidly dry and process the harvested berries. This ensures that they have an optimal fatty acid content and means that the raw material is fully traceable. The residue remaining after fruit extraction is used for recycling products such as natural dyes.

Use of Raw Materials
Digital Training Platform

Modern continuing education in the new "Dermapharm eCampus"

The idea of ensuring employee development regardless of when or where it takes place is growing in significance, and the COVID-19 pandemic has only accelerated the trend towards e-learning. Consequently, in September 2020, the Company launched "Dermapharm eCampus", its own internal training platform, at selected sites. In doing so, we have not just expanded the existing training and education opportunities on offer to our employees but have also laid the foundation to make established training initiatives (including in-person training) more efficient to implement and easier to document. At present, "Dermapharm eCampus" is being used by just under 500 active employees at six Group sites.

The online courses cover regulatory topics (such as data protection, compliance, occupational health and safety, information security) and specialist subject areas (such as drug safety, various product-specific training courses).

The integrated reporting within the system means that those responsible for specific topics always have an overview of how effective their mandatory training programmes are and can further optimise them where necessary. The certificates awarded after successfully completing training serve both as proof of the employee's individual development and as evidence for external audits. In 2020, a total of more than 300 employees each completed nine mandatory training courses via "Dermapharm eCampus".

The training platform will gradually be rolled out to the other Dermapharm Group sites over the course of 2021, and the range of training on offer will continually be expanded. By 2022, we are planning to integrate four other companies within "Dermapharm eCampus". In addition, all employees already have access to specialist training courses available via the online training portal of the German Pharmaceutical Industry Association (Bundesverband der Pharmazeutischen Industrie e.V., "BPI"), BPIeCampus.

Digital Training Platform
Contact Person

Investor Relations & Corporate Communications
Dermapharm Holding SE
Britta Hamberger
Tel.: +49 (89) 641 86 – 233
Fax: +49 (89) 641 86 – 165
E-Mail: ir[at]dermapharm[dot]com